Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Zhejiang Huahai and Breckenridge Sign Agreement for Generic HIV Drug

publication date: May 8, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Zhejiang Huahai Pharmaceutical and Breckenridge Pharmaceutical have signed an exclusive marketing and distribution agreement for Huahai’s HIV drug Nevirapine. Breckenridge will market Nevirapine, a generic version of Boehringer Ingelheim’s antiviral HIV drug, Viramune®, in the US after BI’s patent on Viramune expires on May 22, 2012. Deal terms were not disclosed. More details…

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...